Sign in Subscribe
Genetic research

Predicting Chemosensitivity to Gemcitabine and Cisplatin in Non-Small-Cell Lung Cancer Cells

Strategic Insights

— 1 min read

Researchers from Harbin Medical University conducted a study to investigate the relationship between genetic polymorphisms and mRNA expression levels of certain genes and the chemosensitivity of non-small-cell lung cancer cells to gemcitabine and cisplatin. The study used a panel of 17 non-small-cell lung cancer cell lines and found significant correlations between RRM1 and ABCB1 mRNA expression levels and chemosensitivity to gemcitabine and cisplatin, respectively. The study also identified a potential predictive biomarker for gemcitabine chemosensitivity.

Key Takeaways:

  • The study investigated the relationship between genetic polymorphisms and mRNA expression levels of RRM1, ERCC1, ABCB1, and MTHFR genes and the chemosensitivity of non-small-cell lung cancer cells to gemcitabine and cisplatin.
  • The study found significant correlations between RRM1 mRNA expression levels and chemosensitivity to gemcitabine (r = 0.6533, p = 0.0045) and ABCB1 mRNA expression levels and chemosensitivity to cisplatin (r = -0.5459, p = 0.0287).
  • The MTHFR 1298A C polymorphism was associated with gemcitabine chemosensitivity, but this association requires further functional analysis and investigation in prospective clinical studies.
  • The study suggests that mRNA expression levels of RRM1 and ABCB1 genes may be useful indicators of chemosensitivity to gemcitabine and cisplatin, respectively.

Statistics:

  • 17 non-small-cell lung cancer cell lines were used in the study.
  • The study found a significant correlation between RRM1 mRNA expression levels and chemosensitivity to gemcitabine (r = 0.6533, p = 0.0045).
  • The study found a significant correlation between ABCB1 mRNA expression levels and chemosensitivity to cisplatin (r = -0.5459, p = 0.0287).
  • The MTHFR 1298A C polymorphism showed a tendency to be more chemosensitive to gemcitabine (p = 0.0440).

Sources:

  • Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells. Pharmacogenomics, 2015;16(1):23-34.
  • Harbin Medical University, Key Laboratory of Medical Genomics, Heilongjiang Higher Education Institute, Harbin 150081, People's Republic of China.
  • Future Medicine Ltd, Unitec House, 3RD Floor, 2 Albert Place, Finchley Central, London, N3 1QB, England.

Read more